Amryt Pharma PLC (LON:AMYT) was down 0.9% during mid-day trading on Wednesday . The stock traded as low as GBX 106.60 ($1.39) and last traded at GBX 111 ($1.45), approximately 6,963 shares traded hands during trading. A decline of 96% from the average daily volume of 184,629 shares. The stock had previously closed at GBX 112 ($1.46).
Separately, Shore Capital restated a “house stock” rating on shares of Amryt Pharma in a research note on Tuesday, October 1st.
The company has a debt-to-equity ratio of 101.78, a quick ratio of 1.23 and a current ratio of 1.60. The firm has a market capitalization of $169.67 million and a P/E ratio of -10.28. The stock has a fifty day moving average price of GBX 117.02 and a two-hundred day moving average price of GBX 60.29.
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand.
Read More: What is a Backdoor Roth IRA?
Receive News & Ratings for Amryt Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma and related companies with MarketBeat.com's FREE daily email newsletter.